Key result
Decreased REVEAL risk scores over twelve months are linked to ~94% subsequent one-year survival.
Why the study?
The prognostic implications of changes in REVEAL risk scores and individual risk-score parameters over 12 months in pulmonary arterial hypertension patients were not previously evaluated.
Does the change in REVEAL risk score over 12 months predict subsequent 1-year survival in patients with pulmonary arterial hypertension?
Cohort (n=2,529)
Does the change in REVEAL risk score over 12 months predict subsequent 1-year survival in patients with pulmonary arterial hypertension?
Absolute Event Rate: 93.7% vs 90.3%
Serial assessments of the REVEAL risk score over 12 months strongly predict subsequent 1-year survival in patients with pulmonary arterial hypertension, supporting its use for monitoring disease trajectory and guiding treatment modifications.
No takes yet. Share an insight, caveat, or question.
REVEAL score changes over 12 months were associated with survival differences; leaves open whether serial monitoring should guide PAH management.
Benza et al. (2014) conducted a cohort in pulmonary arterial hypertension (n=2,529). Decreased REVEAL risk score vs. Unchanged REVEAL risk score was evaluated on 1-year survival. A decreased REVEAL risk score over 12 months was associated with a 93.7% subsequent 1-year survival, compared to 90.3% for unchanged and 84.6% for increased risk scores.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: